• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treatment of pembrolizumab and chemotherapy results in pulmonary lymphoepithelioma-like carcinoma progression through harboring secondary amplification of PI3KCA and IL-7R.

作者信息

Chen Mei-Ting, Wang Zhao, Yuan Meng, Fang Xiao-Jie, Lin Tong-Yu

机构信息

Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, 510623, China.

出版信息

Lung Cancer. 2020 Jun;144:87-89. doi: 10.1016/j.lungcan.2020.03.018. Epub 2020 Mar 18.

DOI:10.1016/j.lungcan.2020.03.018
PMID:32331790
Abstract
摘要

相似文献

1
Treatment of pembrolizumab and chemotherapy results in pulmonary lymphoepithelioma-like carcinoma progression through harboring secondary amplification of PI3KCA and IL-7R.帕博利珠单抗和化疗治疗导致肺淋巴上皮瘤样癌进展，原因是存在PI3KCA和IL-7R的继发性扩增。
Lung Cancer. 2020 Jun;144:87-89. doi: 10.1016/j.lungcan.2020.03.018. Epub 2020 Mar 18.
2
Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.帕博利珠单抗对比标准治疗化疗用于 PD-L1 阳性（>50%）转移性鳞状和非鳞状非小细胞肺癌一线治疗的成本效果分析。在法国。
Lung Cancer. 2019 Jan;127:44-52. doi: 10.1016/j.lungcan.2018.11.008. Epub 2018 Nov 23.
3
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.帕博利珠单抗联合化疗对比单纯化疗用于无肿瘤 PD-L1 表达的晚期非小细胞肺癌患者：3 项随机对照研究的汇总分析。
Cancer. 2020 Nov 15;126(22):4867-4877. doi: 10.1002/cncr.33142. Epub 2020 Sep 11.
4
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.帕博利珠单抗对比化疗用于 PD-L1 阳性非小细胞肺癌。
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
5
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.帕博利珠单抗联合 CC-486 与安慰剂联合帕博利珠单抗治疗既往治疗的晚期非小细胞肺癌患者的随机 2 期研究。
Eur J Cancer. 2019 Feb;108:120-128. doi: 10.1016/j.ejca.2018.11.028. Epub 2019 Jan 14.
6
Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US.帕博利珠单抗联合化疗对比化疗联合帕博利珠单抗单药一线治疗美国鳞状非小细胞肺癌的成本效果分析。
Curr Med Res Opin. 2019 Jul;35(7):1241-1256. doi: 10.1080/03007995.2019.1571297. Epub 2019 Jan 29.
7
Histologic Transformation in a Patient with Lung Cancer Treated with Chemotherapy and Pembrolizumab.接受化疗和帕博利珠单抗治疗的肺癌患者的组织学转化
J Thorac Oncol. 2017 Jun;12(6):e75-e76. doi: 10.1016/j.jtho.2017.02.006.
8
Endoscopic central airway recanalization to enable first line pembrolizumab treatment in a PD-L1 strongly positive non-small cell lung cancer: a case report.内镜下中央气道再通术使程序性死亡受体-配体1（PD-L1）强阳性非小细胞肺癌患者能够接受一线帕博利珠单抗治疗：一例报告
J Cardiothorac Surg. 2019 Mar 4;14(1):50. doi: 10.1186/s13019-019-0862-6.
9
Advanced non-small cell lung cancer - treatment with Pembrolizumab.晚期非小细胞肺癌——帕博利珠单抗治疗
Rev Assoc Med Bras (1992). 2020 Mar;66(3):256. doi: 10.1590/1806-9282.66.3.256.
10
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.既往放疗与帕博利珠单抗治疗非小细胞肺癌的临床活性及毒性：KEYNOTE-001 1期试验的二次分析
Lancet Oncol. 2017 Jul;18(7):895-903. doi: 10.1016/S1470-2045(17)30380-7. Epub 2017 May 24.

引用本文的文献

1
Anti-PD-1 antibodies, a novel treatment option for advanced chemoresistant pulmonary lymphoepithelioma carcinoma.抗 PD-1 抗体，一种晚期化疗耐药性肺淋巴上皮瘤样癌的新型治疗选择。
Front Immunol. 2022 Dec 6;13:1001414. doi: 10.3389/fimmu.2022.1001414. eCollection 2022.
2
PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma.PD-1/PD-L1 联合 LAG3 与转移性原发性肺淋巴上皮瘤样癌中免疫检查点抑制剂的临床活性相关。
Front Immunol. 2022 Oct 3;13:951817. doi: 10.3389/fimmu.2022.951817. eCollection 2022.
3
Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study.
多原发部位淋巴上皮样癌的临床特征和治疗结局：一项基于人群、多中心、真实世界研究。
BMC Pulm Med. 2022 Sep 22;22(1):360. doi: 10.1186/s12890-022-02097-6.